Quinoxaline

Quinoxaline

SCHEMBL150387

c1ccc2nccnc2c1.c1ccc2ncncc2c1

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.83
PIK3CD O00329 1/20 0.54
PIK3CA P42336 1/20 0.54
ALDH1A1 P00352 1/20 0.52
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
CYP2A6 P11509 1/20 0.41
CYP1A2 P05177 2/20 0.40
TDO2 P48775 2/20 0.39
NPC1 O15118 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GPR3 P46089 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phthalazine SCHEMBL27500832 0.93 EGFR (0.71) EGFRPIK3CDPIK3CAALDH1A1PDGFRB
Quinazoline SCHEMBL29356169 0.91 EGFR (1.00) EGFRPIK3CDPIK3CAALDH1A1PDGFRB
Quinazoline SCHEMBL29490398 0.91 EGFR (1.00) EGFRPIK3CDPIK3CAALDH1A1PDGFRB
Quinazoline SCHEMBL22833783 0.91 EGFR (1.00) EGFRPIK3CDPIK3CAALDH1A1PDGFRB
Quinazoline SCHEMBL5920 0.91 EGFR (1.00) EGFRPIK3CDPIK3CAALDH1A1PDGFRB
Quinoline SCHEMBL156755 0.90 EGFR (0.80) EGFRPIK3CDPIK3CAALDH1A1PDGFRB
SCHEMBL3196932 0.89 EGFR (0.95) EGFRPIK3CDPIK3CAALDH1A1PDGFRB
Quinazoline SCHEMBL1119374 0.89 EGFR (0.95) EGFRPIK3CDPIK3CAALDH1A1PDGFRB
Quinazoline SCHEMBL4487630 0.89 EGFR (0.95) EGFRPIK3CDPIK3CAALDH1A1PDGFRB
Quinazoline SCHEMBL21055790 0.89 EGFR (0.95) EGFRPIK3CDPIK3CAALDH1A1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101932317-A Stable pharmaceutical composition ASAHI KASEI PHARMA CORP 2010-12-29 CN claimed
CN-1418192-A Pharmaceutical compositions containing azetidine derivatives novel azetidine derivatives and preparation thereof AVENTIS PHARMA SA (FR) 2003-05-14 CN claimed
CN-1411440-A Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and process for preparing same AVENTIS PHARMA SA (FR) 2003-04-16 CN claimed
CN-117430641-A Organic electroluminescent material and device 环球展览公司 2024-01-23 CN disclosed
CN-115298846-A Organic electroluminescent element 日铁化学材料株式会社 2022-11-04 CN disclosed
US-11302872-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2022-04-12 US disclosed
US-9698411-B2 Electrode for battery and production method thereof, nonaqueous electrolyte battery, battery pack, and active material KABUSHIKI KAISHA TOSHIBA (JP) 2017-07-04 US disclosed
EP-2677574-B1 BATTERY ELECTRODE AND MANUFACTURING METHOD THEREOF, NON-AQUEOUS ELECTROLYTE BATTERY, BATTERY PACK, AND ACTIVE MATERIAL TOSHIBA KK (JP) 2017-06-21 EP disclosed
US-20170069848-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2017-03-09 US disclosed
CN-103210531-B Battery electrode and method for producing same, nonaqueous electrolyte battery, battery pack, and active material TOSHIBA CORP. (JP) 2016-06-01 CN disclosed
CN-102403509-B Battery electrode, the method for preparing described battery electrode, nonaqueous electrolyte battery, battery pack and active material TOSHIBA CORP (JP) 2016-05-04 CN disclosed
CN-1660720-A Method for producing molecular compound NIPPON SODA CO (JP) 2005-08-31 CN disclosed
CN-1205153-C Method for producing molecular compound NIPPON SODA CO (JP) 2005-06-08 CN disclosed
WO-2005009994-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 WO disclosed
CN-1187325-C Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof AVENTIS PHARMA SA (FR) 2005-02-02 CN disclosed
CN-1479704-A Method for producing molecular compound �ձ�������ʽ���� 2004-03-03 CN disclosed
CN-1411440-A Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and process for preparing same AVENTIS PHARMA SA (FR) 2003-04-16 CN disclosed
CN-1399733-A Salt-like structured silicates as charge control agents CLARIANT GMBH (DE) 2003-02-26 CN disclosed
CN-1067419-C Reactive dyestuffs their preparation and their use BAYER AG (DE) 2001-06-20 CN disclosed
CN-1106845-A Reactive dyestuffs their preparation and their use BAYER AG (DE) 1995-08-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170069848-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES EML4, IKZF2, BPTF EGFR 1000/4885PIK3CD 4172/4885PIK3CA 4481/4885
US-11302872-B2 Organic electroluminescent materials and devices EML4, IKZF2, BPTF EGFR 1000/4885PIK3CD 4172/4885PIK3CA 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.